Profile of Diabetes Mellitus in Benign Protate Hyperplation’s Patients with Urinary Retention in Dr. Soetomo 2016
Introduction: Benign prostatic hyperplasia (BPH) develops inevitably related to age in almost all men starting around the age of 40 years. LUTS is the most common manifestation of BPH. There were several risk factors that play a role in the BPH and LUTS, one of which is diabetes mellitus. The incidence of diabetes mellitus is increasing throughout the world. In 2015, it was estimated that 30.3 million Americans (9.4%) and 3.4 million Canadians (9.3%) were diagnosed with diabetes. About 5% - 10% are diagnosed with type I, and around 90% - 95% are diagnosed with type II. The burden of the disease caused by diabetes is quite high and continues to increase in every country. It is estimated that the global prevalence of people with diabetes in 2013 as many as 382 million people will increase to 592 million by 2035. The exact etiology of BPH is still unknown. Acute urinary retention (AUR) is the most frequent urological emergency. This study aims to find out the number of occurrences of diabetes mellitus in BPH patients with urinary retention in Dr. Soetomo General Hospital from January to December 2016.
Methods: This research used descriptive research design. Population in this study was BPH patients with acute urinary retention in Dr. Soetomo General Hospital in 2016. The total sampling method was used. The variable studied was diabetes mellitus. The data was obtained from the patient's medical record.
Results: In this study, 62 subjects were found with 11 subjects with positive diabetes mellitus (17.7%) and 43 subjects with negative diabetes mellitus (69.4%).
Conclusion: From the results of the study, it was found that there were 17.7% of BPH patients with acute urinary retention who had diabetes mellitus.
McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. The Journal of urology. 2011; 185: 1793-803.
Oelke M, Höfner K, Jonas U, Laval K-U and Tunn U. Benign Prostatic Hyperplasia: Terminology and Assessment. Deutsches Ärzteblatt. 2007; 104: 2261-7.
Selius B and Subedi R. Urinary Retention in Adults: Diagnosis and Initial Management. American Academy of Family Physicians. 2008; 77: 643-6.
Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005; 7 Suppl 9: S3-S14.
Chapple C and Abrams P. Male Lower Urinary Tract Symptoms (LUTS): An International Consultation on Male LUTS. Montréal: Société Internationale d'Urologie, 2013.
Breyer BN and Sarma AV. Hyperglycemia and insulin resistance and the risk of BPH/LUTS: an update of recent literature. Current urology reports. 2014; 15: 462.
Parsons JK. Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep. 2010; 5: 212-8.
Organization WH. Diabetes mellitus: (2018, accessed November 23rd 2018).
American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes care. 2010; 33 Suppl 1: S62-S9.
Nyman MA, Schwenk NM and Silverstein MD. Management of urinary retention: rapid versus gradual decompression and risk of complications. Mayo Clinic proceedings. 1997; 72: 951-6.
Curtis LA, Dolan TS and Cespedes RD. Acute urinary retention and urinary incontinence. Emergency medicine clinics of North America. 2001; 19: 591-619.
Gacci M, Vignozzi L, Sebastianelli A, et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate cancer and prostatic diseases. 2013; 16: 101-6.
Wang Z, Xiao X, Ge R, et al. Metformin inhibits the proliferation of benign prostatic epithelial cells. PloS one. 2017; 12: e0173335.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions
3. The formal legal aspect of journal publication accessibility refers to Creative Commons Atribution-Share Alike 4.0 (CC BY-SA).